These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 26915463)
81. Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia. Gohil SH; Evans R; Harasser M; El-Kholy M; Paredes-Moscosso SR; Della Peruta M; Nathwani AC Br J Haematol; 2019 Jul; 186(2):380-382. PubMed ID: 30957227 [No Abstract] [Full Text] [Related]
82. Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related? Sachanas S; Pangalis GA; Moschogiannis M; Yiakoumis X; Koulieris E; Tsirkinidis P; Kalpadakis C; Rontogianni D Anticancer Res; 2017 Jun; 37(6):3277-3280. PubMed ID: 28551676 [TBL] [Abstract][Full Text] [Related]
83. Ibrutinib has some activity in Richter's syndrome. Giri S; Hahn A; Yaghmour G; Martin MG Blood Cancer J; 2015 Jan; 5(1):e277. PubMed ID: 25635530 [No Abstract] [Full Text] [Related]
84. Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib. Shumilov E; Wulf G; Ströbel P; Hasenkamp J; Hellige N; Bleckmann A; Haase D; Braulke F; Jung W; Schanz J; Binder M; Trümper L; Bacher U Leuk Lymphoma; 2016 Oct; 57(10):2476-80. PubMed ID: 26916814 [No Abstract] [Full Text] [Related]
85. Comparative Analysis of Risk Prediction Scores for Treatment-Emergent Atrial Fibrillation Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. Babbili A; Lakra R; Thotamgari SR; Gaddam SJ; Grewal US; Dominic P Am J Ther; 2024 Jul-Aug 01; 31(4):e453-e455. PubMed ID: 38305826 [No Abstract] [Full Text] [Related]
86. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. Schliffke S; Akyüz N; Ford CT; Mährle T; Thenhausen T; Krohn-Grimberghe A; Knop S; Bokemeyer C; Binder M Leukemia; 2016 Nov; 30(11):2232-2234. PubMed ID: 27220665 [No Abstract] [Full Text] [Related]
87. [Cryptococcal meningitis in the treatment of CLL with ibrutinib: a case report and literature review]. Zhang H; Zhang XH; Chen P; Li BZ Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):428-430. PubMed ID: 32536143 [No Abstract] [Full Text] [Related]
88. Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program. Hillmen P; Diels J; Healy N; Iraqi W; Aschan J; Wildgust M Haematologica; 2018 May; 103(5):e204-e206. PubMed ID: 29419428 [No Abstract] [Full Text] [Related]
89. Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report. Grossi O; Pineau S; Sadot-Lebouvier S; Hay B; Delaunay J; Miailhe AF; Bretonnière C; Jeddi F; Lavergne RA; Le Pape P Clin Microbiol Infect; 2019 Feb; 25(2):261-263. PubMed ID: 30691617 [No Abstract] [Full Text] [Related]
90. Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement. Hiemcke-Jiwa LS; Leguit RJ; Radersma-van Loon JH; Westerweel PE; Rood JJM; Doorduijn JK; Huibers MMH; Minnema MC Leuk Lymphoma; 2018 May; 59(5):1256-1259. PubMed ID: 28849690 [No Abstract] [Full Text] [Related]
91. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. Winqvist M; Andersson PO; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Späth F; Hansson L; Österborg A; Haematologica; 2019 May; 104(5):e208-e210. PubMed ID: 30514799 [No Abstract] [Full Text] [Related]
92. Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia. Kiss R; Alpár D; Gángó A; Nagy N; Eyupoglu E; Aczél D; Matolcsy A; Csomor J; Mátrai Z; Bödör C Haematologica; 2019 Jan; 104(1):e38-e41. PubMed ID: 30262564 [No Abstract] [Full Text] [Related]
93. Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib. Jiang F; Verma P Ann Allergy Asthma Immunol; 2018 Mar; 120(3):324-325. PubMed ID: 29174859 [No Abstract] [Full Text] [Related]
94. Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib. England JT; Leitch HA Leuk Lymphoma; 2018 Mar; 59(3):752-754. PubMed ID: 28728450 [No Abstract] [Full Text] [Related]
95. Optic Neuropathy Due to Chronic Lymphocytic Leukemia Proven With Optic Nerve Sheath Biopsy. Khan K; Malik AI; Almarzouqi SJ; Morgan ML; Yalamanchili S; Chevez-Barrios P; Lee AG J Neuroophthalmol; 2016 Mar; 36(1):61-6. PubMed ID: 26436987 [TBL] [Abstract][Full Text] [Related]
96. Occult HBV reactivation induced by ibrutinib treatment: a case report. de Jésus Ngoma P; Kabamba B; Dahlqvist G; Sempoux C; Lanthier N; Shindano T; Van Den Neste E; Horsmans Y Acta Gastroenterol Belg; 2015 Dec; 78(4):424-6. PubMed ID: 26712054 [TBL] [Abstract][Full Text] [Related]